Qiang Wang

About me

My educational background is Clinical Medicine/General Surgery and I worked as a hepatobiliary surgeon in my country. I was registered as a PhD student at Professor Torkel B. Brismar Group in June 2018.

Research fields: liver function; liver growth/regeneration; gadoxetic acid enhanced MRI; radiomics & machine learning; hepatocellular carcinoma.

Research description

My PhD study is centered around how to accurately evaluate the liver function, especially the future liver remnant part, in patients with hepatocellular carcinoma before liver resection. We aim to establish non-invasive, accurate and reliable imaging biomarkers to evaluate (regional) liver function quantitatively based on preoperative gadoxetic acid enhanced MRI. With an ever-growing progress of artificial intelligence in the medical field, my current research is also making an attempt to apply machine learning approach (such as radiomics) to evaluate liver function, for instance to predict post-hepatectomy liver failure. We expect our research findings can supply a comprehensive estimation of the liver function for patients before liver resection, increase the number of patients as candidates for liver resection and assist to provide a safer and successful operation.

 

Publications

Multimodal perioperative assessment of liver function and volume in patients undergoing hepatectomy for colorectal liver metastasis: a comparison of the indocyanine green retention test, 99mTc mebrofenin hepatobiliary scintigraphy and gadoxetic acid enhanced MRI.

Wang Q*, Brismar TB, Gilg S, Jonas E, Nilsson H, Tzortzakakis A, Isaksson B, Axelsson R, Sparrelid E.

British Journal of Radiology. 2022 Sep 16:20220370. doi: 10.1259/bjr.20220370. 

A Radiomics Model Based on Gd-EOB-DTPA-Enhanced MRI for the Prediction of Microvascular Invasion in Solitary Hepatocellular Carcinoma ≤ 5 cm.

Qu C, Wang Q*, Li C, Xie Q, Cai P, Yan X, Sparrelid E, Zhang L, Ma K, Brismar TB.

Frontiers in Oncology. 2022 May 19;12:831795. doi: 10.3389/fonc.2022.831795. 

Quantitative evaluation of liver function with gadoxetic acid enhanced MRI: Comparison among signal intensity-, T1-relaxometry-, and dynamic-hepatocyte-specific-contrast-enhanced MRI- derived parameters.

Wang Q, Kesen S, Liljeroth M, Nilsson H, Zhao Y, Sparrelid E, Brismar TB. 

Scandinavian journal of Gastroenterology. 2022 Feb 2:1-8. doi: 10.1080/00365521.2022.2032321. Epub ahead of print. 

Immunological Classification of Pancreatic Carcinomas to Identify Immune Index and Provide a Strategy for Patient Stratification.

Chen Y, Chen D, Wang Q, Xu Y, Huang X, Haglund F, Su H.

Frontiers in Immunology. 2022 Jan 17;12:719105. doi: 10.3389/fimmu.2021.719105. 

Radiomics Models for Predicting Microvascular Invasion in Hepatocellular Carcinoma: A Systematic Review and Radiomics Quality Score Assessment. 

Wang Q, Li C, Zhang J, Hu X, Fan Y, Ma K, Sparrelid E, Brismar TB.

Cancers (Basel). 2021 Nov 22;13(22):5864. doi: 10.3390/cancers13225864. 

Sequential Portal Vein Embolization and Percutaneous Radiofrequency Ablation for Future Liver Remnant Growth: A Minimally Invasive Alternative to ALPPS Stage-1 in Treatment of Hepatocellular Carcinoma. 

Wang Q, Ji Y, Brismar TB, Chen S, Li C, Jiang J, Mu W, Zhang L, Sparrelid E, Ma K.

Frontiers in Surgery. 2021 Sep 30;8:741352. doi: 10.3389/fsurg.2021.741352. 

Predictive value of gadoxetic acid-enhanced MRI for posthepatectomy liver failure: a systematic review. 

Wang Q, Wang A, Sparrelid E, Zhang J, Zhao Y, Ma K, Brismar TB.

European Radiology. 2021 Sep 25. doi: 10.1007/s00330-021-08297-8. Epub ahead of print. 

Rescue radiofrequency ablation or percutaneous ethanol injection: a strategy for failed RALPPS stage-1 in patients with cirrhosis-related hepatocellular carcinoma.

Wang Q, Chen S, Yan J, Brismar T, Sparrelid E, Qu C, Ji Y, Chen S, Ma K.

BMC Surgery. 2021 May 18;21(1):246. doi: 10.1186/s12893-021-01241-z. 

Academic honours, awards and prizes

Medicinsk Diagnostik Karolinska Kliniknära FoU 2022.

Member of National Clinical Research School in Chronic Inflammatory Diseases (NCRSCID) (2020-2022).